化合物 T11248 T11248

Product Introduction
Bioactivity


英文名: Evogliptin tartrate

描述: Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation. Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity.

体外活性: Evogliptin tartrate inhibits the TNF-α-mediated transcriptional activation of ICAM-1 and VCAM-1. Evogliptin tartrate inhibits inflammatory responses via suppression of adhesion molecules induced by TNF-α. And TNF-α-mediated activation of NF-κB is ameliorated by evogliptin via the interaction of NF-κB with SIRT1.Evogliptin tartrate significantly inhibits the TNF-α-mediated induction of ICAM-1 and VCAM-1 expression in a concentration-dependent manner (IC50 = 0.30 and 0.25 μM, respectively).

体内活性: Evogliptin tartrate inhibits the formation of atherosclerotic lesions by reducing vasoinflammation and increases plaque stability.Evogliptin tartrate (37.5-150 mg/kg; p.o.; daily; for 12 weeks) reduces the high-fat diet-induced atherosclerotic plaque area in the ApoE?/? mouse model.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: DA1229 Tartrate | Evogliptin tartrate | Evogliptin Tartrate | DA-1229 Tartrate | DA 1229 Tartrate

相关产品: Trelagliptin succinate | Alogliptin | Sitagliptin phosphate monohydrate | Vildagliptin | 3-Pyridylacetic acid hydrochloride | Talabostat mesylate | Trelagliptin | Denagliptin | Linagliptin | Saxagliptin

化合物 T11248 T11248信息由TargetMol中国为您提供，如您想了解更多关于化合物 T11248 T11248报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途